The Randomized Controlled Trial for Evaluating the Efficacies of Tolvaptan in Patients with ascites in hepatic edema

The Randomized Controlled Trial for Evaluating the Efficacies of Tolvaptan in Patients with ascites in hepatic edema - The Efficacies of Tolvaptan in Patients with ascites in hepatic edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015218

Enrollment

Registered

2014-09-24

Start date

2014-07-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

Add oral tolvaptan 7.5mg/day to the conventional therapy for a week Add oral furosemide 40mg/day to the conventional therapy for a week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with liver cirrohsis with ascites in hepatic edema. 2)Patients given oral furosemide 20-100mg/day and Spironolactone 25mg-200mg at the time of enrolling.

Exclusion criteria

Exclusion criteria: 1)The anuric patients 4)Patients with urinary retention 3)Serum Na >=147mEq/L

Design outcomes

Primary

Measure	Time frame
change of body weight	—

Secondary

Measure	Time frame
1) change of volume of ascites 2) change of urine output 3) symptoms of volume overload	—

Countries

Japan

Contacts

Public Contactuojima haruki

shonan kamakura general hospital department of gastroenterology

kiruha555@yahoo.co.jp0467-46-1717

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026